entertainment -WSS

entertainment

author：fashion 2025-09-27 09:58:32 - browse：79

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Infant mortality in U.S. rose last year for first time in decades: CDC

knowledge

explore

WSS

Infant mortality in U.S. rose last year for first time in decades: CDC

Readout LOUD podcast: ESMO highlights & Roivant's big deal

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Medicare proceeds with plan to claw back hospital funds

Petition to FDA: Get the lead out of consumer hair dyes

Bulgari apologizes to China for listing Taiwan as a country after online backlash

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

Oak trusses raised to roof of fire

In age of alternative facts, a scholarly course on calling out crap

Living with Fabry disease, a condition that causes chronic pain

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Lung cancer screening guidelines updated for cigarette smokers

The high cost of giving birth even with insurance

All of Us, NIH's precision medicine initiative, gets a big boost

New air purifier tech could be key to improving indoor air quality

What is microchimerism and how does it affect maternal health?

Wikipedia

Beach reads and more: STAT's 2023 summer book list

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

How neuroscience research could help beat back brain cancer

How to convince healthy people to buy insurance

The health care issue Democrats can’t solve: hospital reform

knowledge

entertainment

explore

leisure time